

Overview

Useful For

Monitoring whole blood cyclosporine concentration during therapy, particularly in individuals coadministered cytochrome P450 (CYP) 3A4 substrates, inhibitors, or inducers

Adjusting dose to optimize immunosuppression while minimizing toxicity

Evaluating patient compliance

Method Name

High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS)

NY State Available

No

Specimen

Specimen Type

Whole Blood EDTA

Specimen Required

Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions:

1. Collect specimen immediately before a scheduled dose.
2. **Do not centrifuge.**
3. Send whole blood specimen in original tube. **Do not aliquot.**

Additional Information: Therapeutic range applies to trough specimens collected immediately prior to a.m. dose.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

[-Renal Diagnostics Test Request \(T830\)](#)

[-Therapeutics Test Request \(T831\)](#)

Specimen Minimum Volume

1 mL

Reject Due To

Gross hemolysis	OK
-----------------	----

Gross lipemia	OK
Gross icterus	OK
Clotted specimens	Reject

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole Blood EDTA	Refrigerated (preferred)	14 days	
	Ambient	14 days	
	Frozen	14 days	

Clinical & Interpretive

Clinical Information

Cyclosporine is a lipophilic polypeptide used to prevent rejection after solid organ transplantation; it suppresses T-cell activation by inhibiting calcineurin to decrease interleukin-2 (IL-2) production. There is substantial interpatient variability in absorption, half-life, and other pharmacokinetic parameters. Cyclosporine is extensively metabolized by cytochrome P450 (CYP) 3A4 to at least 30 less-active metabolites, many of which are detected by immunoassays. Cyclosporine is known for many drug interactions, including increased neuro- and nephrotoxicity when coadministered with antibiotics, antifungals, or other immunosuppressants. Cyclosporine has a narrow therapeutic range with frequent adverse effects making therapeutic drug monitoring essential.

With 80% of cyclosporine sequestered in erythrocytes, whole blood is the preferred specimen for analysis. Dose is adjusted initially (up to 2 months posttransplant) to maintain concentrations generally between 150 and 400 ng/mL. Target trough concentrations vary according to clinical protocol and depend on type of allograft, risk of rejection, concomitant immunosuppressive drugs, and toxicity. After the first 2 postoperative months, the target range is generally lower, between 75 and 300 ng/mL. Conversion between formulations is generally done at the same dose but with drug monitoring.

Reference Values

100-400 ng/mL (trough)

Target steady-state trough concentrations vary depending on the type of transplant, concomitant immunosuppression, clinical/institutional protocols, and time post-transplant. Results should be interpreted in conjunction with this clinical information and any physical signs/symptoms of rejection/toxicity.

Interpretation

Most individuals display optimal response to cyclosporine with trough whole blood levels 100 to 400 ng/mL. Preferred therapeutic ranges may vary by transplant type, protocol, and comedication.

Therapeutic ranges are based on specimens collected at trough (ie, immediately before the next scheduled dose). Higher results will be obtained when the blood is drawn at other times.

This test may also be used to analyze cyclosporine levels 2 hours after dosing (C2 concentrations); trough therapeutic

ranges do not apply to C2 specimens.

The assay is specific for cyclosporine; it does not cross-react with cyclosporine metabolites, sirolimus, sirolimus metabolites, tacrolimus, or tacrolimus metabolites. Results by liquid chromatography with detection by tandem mass spectrometry are approximately 30% less than by immunoassay.

Cautions

The recommended therapeutic ranges described above apply to trough specimens collected just before a dose. Blood drawn at other times will yield higher results.

Clinical Reference

1. Moyer TP, Post GR, Sterioff S, Anderson CF: Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. *Mayo Clin Proc.* 1988;63(3):241-247
2. Kahan BD, Keown P, Levy GA, Johnston A: Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. *Clin Ther.* 2002;24(3):330-350
3. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL: Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy, and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. *Drugs.* 2001;61(13):1957-2016
4. Milone MC, Shaw LM: Therapeutic drugs and their management. In: Rifai N, Chiu RWK, Young I, Burnham CAD, eds. *Tietz Textbook of Laboratory Medicine.* 7th ed. Elsevier; 2023:420-453

Performance**Method Description**

Blood specimens are subjected to protein precipitation. The resulting supernatant is analyzed by liquid chromatography-tandem mass spectrometry. (Bjergum MW, Jannetto PJ, Langman LJ. Simultaneous determination of tacrolimus and cyclosporine A in whole blood by ultrafast LC-MS/MS. *Methods Mol Biol.* 2019;1872:111-118. doi: 10.1007/978-1-4939-8823-5_11)

PDF Report

No

Day(s) Performed

Monday through Sunday

Report Available

Same day/1 day

Specimen Retention Time

14 days

Performing Laboratory Location

Jacksonville

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80158

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
CYSPR	Cyclosporine, B	3520-4

Result ID	Test Result Name	Result LOINC® Value
35143	Cyclosporine, B	3520-4